New‐onset Crohn's disease after interleukin‐17A inhibitor therapy with secukinumab: A report of an unusual case

Abstract

A 32-year-old man with a history of arthropathic psoriasis had regular followup checkups and medications to control his arthropathic psoriasis at our rheumatology outpatient department. He had diarrhea for 20 days and visited our gastroenterology outpatient department. On the basis of the colonoscopy findings, a diagnosis of inflammatory bowel disease (Crohn's disease) was made.We reviewed his medical history and found that he had used secukinumab 2 months before. Pathological examination revealed chronic colitis with severe activity, compatible with inflammatory bowel disease. The biologic was shifted from secukinumab to adalimumab. His diarrhea gradually improved in the following 3 months. A follow-up colonoscopy 6 months after revealed remission of the ileal and colonic ulcers.